Predicting Blood Concentration of Tacrolimus in Patients With Autoimmune Diseases Using Machine Learning Techniques Based on Real-World Evidence

Tacrolimus is a widely used immunosuppressive drug in patients with autoimmune diseases. It has a narrow therapeutic window, thus requiring therapeutic drug monitoring (TDM) to guide the clinical regimen. This study included 193 cases of tacrolimus TDM data in patients with autoimmune diseases at So...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 727245
Main Authors Zheng, Ping, Yu, Ze, Li, Liren, Liu, Shiting, Lou, Yan, Hao, Xin, Yu, Peng, Lei, Ming, Qi, Qiaona, Wang, Zeyuan, Gao, Fei, Zhang, Yuqing, Li, Yilei
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 24.09.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Tacrolimus is a widely used immunosuppressive drug in patients with autoimmune diseases. It has a narrow therapeutic window, thus requiring therapeutic drug monitoring (TDM) to guide the clinical regimen. This study included 193 cases of tacrolimus TDM data in patients with autoimmune diseases at Southern Medical University Nanfang Hospital from June 7, 2018, to December 31, 2020. The study identified nine important variables for tacrolimus concentration using sequential forward selection, including height, tacrolimus daily dose, other immunosuppressants, low-density lipoprotein cholesterol, mean corpuscular volume, mean corpuscular hemoglobin, white blood cell count, direct bilirubin, and hematocrit. The prediction abilities of 14 models based on regression analysis or machine learning algorithms were compared. Ultimately, a prediction model of tacrolimus concentration was established through eXtreme Gradient Boosting (XGBoost) algorithm with the best predictive ability ( R 2 = 0.54, mean absolute error = 0.25, and root mean square error = 0.33). Then, SHapley Additive exPlanations was used to visually interpret the variable’s impacts on tacrolimus concentration. In conclusion, the XGBoost model for predicting blood concentration of tacrolimus on the basis of real-world evidence has good predictive performance, providing guidance for the adjustment of regimen in clinical practice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology
Reviewed by: Kurt Neumann, Independent researcher, Kerékteleki, Hungary
Edited by: Kenneth KC Lee, Monash University Malaysia, Malaysia
Shu Chuen Li, The University of Newcastle, Australia
These authors have contributed equally to this work
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.727245